Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. JNJ
stocks logo

JNJ

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
24.13B
+7.14%
2.532
+24.11%
23.05B
+5.27%
2.756
-0.51%
24.82B
+4.53%
2.902
+4.75%
Estimates Revision
The market is revising Upward the revenue expectations for Johnson & Johnson (JNJ) for FY2025, with the revenue forecasts being adjusted by 0.51% over the past three months. During the same period, the stock price has changed by 13.48%.
Revenue Estimates for FY2025
Revise Upward
up Image
+0.51%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+0.07%
In Past 3 Month
Stock Price
Go Up
up Image
+13.48%
In Past 3 Month
Wall Street analysts forecast JNJ stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for JNJ is 207.26 USD with a low forecast of 176.00 USD and a high forecast of 230.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
20 Analyst Rating
Wall Street analysts forecast JNJ stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for JNJ is 207.26 USD with a low forecast of 176.00 USD and a high forecast of 230.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
13 Buy
7 Hold
0 Sell
Moderate Buy
Current: 202.480
sliders
Low
176.00
Averages
207.26
High
230.00
Current: 202.480
sliders
Low
176.00
Averages
207.26
High
230.00
Barclays
Equal Weight
maintain
$176 -> $197
2025-12-02
New
Reason
Barclays
Price Target
$176 -> $197
2025-12-02
New
maintain
Equal Weight
Reason
Barclays raised the firm's price target on Johnson & Johnson to $197 from $176 and keeps an Equal Weight rating on the shares. The firm updated the company's estimates.
Scotiabank
Outperform
initiated
$230
2025-11-12
Reason
Scotiabank
Price Target
$230
2025-11-12
initiated
Outperform
Reason
Scotiabank initiated coverage of Johnson & Johnson with an Outperform rating and $230 price target.
Freedom Capital
Ilya Zubkov
Buy
to
Hold
downgrade
$180 -> $190
2025-10-22
Reason
Freedom Capital
Ilya Zubkov
Price Target
$180 -> $190
2025-10-22
downgrade
Buy
to
Hold
Reason
Freedom Capital analyst Ilya Zubkov downgraded Johnson & Johnson to Hold from Buy with a price target of $190, up from $180. While stating that J&J "once again" exceeded both the firm's expectations and market consensus with its "robust" Q3 results and noting that the company raised its revenue guidance for the third time this year, the firm is downgrading shares as the stock is now trading near its fair value estimate.
Stifel
Hold
maintain
$165 -> $190
2025-10-15
Reason
Stifel
Price Target
$165 -> $190
2025-10-15
maintain
Hold
Reason
Stifel raised the firm's price target on Johnson & Johnson to $190 from $165 and keeps a Hold rating on the shares after the company delivered above-consensus sales and EPS, offered up "bullish" commentary and "repeatedly emphasized their optimism" about the rest-of-2025 outlook and their confidence that the business is now in an "accelerated cycle of growth."
Morgan Stanley
Terence Flynn
Equal Weight
maintain
$178 -> $190
2025-10-15
Reason
Morgan Stanley
Terence Flynn
Price Target
$178 -> $190
2025-10-15
maintain
Equal Weight
Reason
Morgan Stanley analyst Terence Flynn raised the firm's price target on Johnson & Johnson to $190 from $178 and keeps an Equal Weight rating on the shares. J&J announcing a planned separation of its ortho business in conjunction with a "slight" Q3 beat was "a surprise" that should boost the company's outer year growth, the analyst tells investors. The firm tweaks its 2025 and later estimates slightly higher on Q3 results and commentary, the analyst noted.
Raymond James
Outperform
maintain
$174 -> $209
2025-10-15
Reason
Raymond James
Price Target
$174 -> $209
2025-10-15
maintain
Outperform
Reason
Raymond James raised the firm's price target on Johnson & Johnson to $209 from $174 and keeps an Outperform rating on the shares. Despite near-term pressure from Stelara's loss of exclusivity, J&J remains optimistic, pointing to a strong pipeline and divestiture of slower-growth units as drivers of a new growth phase, the analyst tells investors in a research note. Management suggested 2026 consensus estimates may be too conservative, the firm says.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Johnson & Johnson (JNJ.N) is 18.15, compared to its 5-year average forward P/E of 16.15. For a more detailed relative valuation and DCF analysis to assess Johnson & Johnson 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Overvalued
5Y Average PE
16.15
Current PE
18.15
Overvalued PE
17.36
Undervalued PE
14.95

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
12.98
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
13.80
Undervalued EV/EBITDA
12.15

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
4.49
Current PS
0.00
Overvalued PS
4.82
Undervalued PS
4.16
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

JNJ News & Events

Events Timeline

(ET)
2025-12-04
10:20:00
FDA Plans to Reduce Drug Approval Trials, Shares of Icon and Others Drop
select
2025-12-04
09:50:00
FDA Plans to Simplify Medical Product Approvals to One Clinical Study
select
link
2025-12-02 (ET)
2025-12-02
11:30:00
FDA Drug Regulator Richard Pazdur to Retire at Month-End
select
link
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
8.5
12-04Yahoo Finance
PinnedGrowth-Focused Acquisitions: Evolving Strategies in Logistics Expansion

  • Neace Ventures' Strategic Acquisitions: Neace Ventures has acquired J&J Transportation Consultants and Thoroughbred Transportation to enhance its Talon Logistics division, significantly increasing capacity and service offerings in the logistics sector.

  • Market Trends in Logistics: The logistics industry is shifting towards growth through acquisitions rather than organic expansion, as companies seek to provide comprehensive, integrated solutions to meet evolving customer demands.

  • M&A Activity Overview: While overall M&A activity in logistics has slowed, larger-scale acquisitions are occurring, particularly in North America and APAC, indicating a strategic focus on scale amidst economic pressures.

  • Impact on Industry Dynamics: The consolidation trend may lead to fewer specialized independent players and more full-service providers, increasing competitive pressure on smaller firms that may need to adapt through partnerships or investments.

[object Object]
Preview
9.0
12-04Benzinga
Bristol Myers Delays Data Release for Important Alzheimer's Psychosis Study Due to Irregularities

  • Bristol Myers Squibb's ADEPT-2 Study: The company is enrolling additional patients in the ADEPT-2 Phase 3 study, which evaluates the safety and efficacy of Cobenfy for psychosis associated with Alzheimer's disease dementia, following a recommendation from the Data Monitoring Committee.

  • Cobenfy's Current Status: Cobenfy is already approved for treating schizophrenia in adults, and the ADEPT-2 study aims to assess its impact on hallucinations and delusions, with results expected by the end of 2026.

  • Market Reaction: Bristol Myers Squibb shares rose by 5.77% to $51.03, reflecting investor optimism despite previous setbacks in other clinical trials.

  • Recent Trial Discontinuation: The company recently halted the Phase 3 Librexia ACS trial of milvexian due to an interim analysis indicating it was unlikely to meet primary efficacy endpoints.

[object Object]
Preview
5.0
12-04Yahoo Finance
2025 Intraocular Lens Market Competitor Analysis: Recent Developments, Strategies, Sustainability Benchmarks, Product Launches, Key Personnel, and Revenue Insights

  • Market Growth Projection: The intraocular lens (IOL) market is expected to grow from $4.46 billion in 2024 to $7.16 billion by 2033, with a compound annual growth rate (CAGR) of 5.41%, driven by the rising prevalence of cataracts and an aging population.

  • Technological Advancements: Innovations in lens technology, including multifocal and toric lenses, are enhancing visual outcomes and increasing the adoption of premium lens types, particularly in emerging markets.

  • Key Industry Players: Major companies like Alcon, Johnson & Johnson, and Bausch + Lomb are leading the market with new product launches and advancements, such as the Clareon Vivity IOL and the enVista Envy full-range IOL.

  • Sustainability Focus: The industry is increasingly prioritizing sustainability, with companies implementing environmental goals and initiatives related to renewable energy, waste management, and sustainable packaging.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Johnson & Johnson (JNJ) stock price today?

The current price of JNJ is 202.48 USD — it has decreased -1.39 % in the last trading day.

arrow icon

What is Johnson & Johnson (JNJ)'s business?

Johnson & Johnson and its subsidiaries are engaged in the research and development, manufacture, and sale of a range of products in the healthcare field. The Company’s segments include Innovative Medicine and MedTech. The Innovative Medicine segment is focused on various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, cardiovascular and metabolism. Its products include REMICADE (infliximab), SIMPONI (golimumab), SIMPONI ARIA (golimumab), STELARA (ustekinumab), TREMFYA (guselkumab), EDURANT (rilpivirine), and INVEGA SUSTENNA/XEPLION (paliperidone palmitate). The MedTech segment includes a portfolio of products used in cardiovascular, orthopedics, surgery, and vision categories. The Cardiovascular portfolio includes electrophysiology products to treat heart rhythm disorders and circulatory restoration products (Shockwave) for the treatment of calcified coronary artery disease (CAD) and peripheral artery disease (PAD).

arrow icon

What is the price predicton of JNJ Stock?

Wall Street analysts forecast JNJ stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for JNJ is 207.26 USD with a low forecast of 176.00 USD and a high forecast of 230.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Johnson & Johnson (JNJ)'s revenue for the last quarter?

Johnson & Johnson revenue for the last quarter amounts to 23.99B USD, increased 6.77 % YoY.

arrow icon

What is Johnson & Johnson (JNJ)'s earnings per share (EPS) for the last quarter?

Johnson & Johnson. EPS for the last quarter amounts to 2.12 USD, increased 90.99 % YoY.

arrow icon

What changes have occurred in the market's expectations for Johnson & Johnson (JNJ)'s fundamentals?

The market is revising Upward the revenue expectations for Johnson & Johnson (JNJ) for FY2025, with the revenue forecasts being adjusted by 0.51% over the past three months. During the same period, the stock price has changed by 13.48%.
arrow icon

How many employees does Johnson & Johnson (JNJ). have?

Johnson & Johnson (JNJ) has 138100 emplpoyees as of December 05 2025.

arrow icon

What is Johnson & Johnson (JNJ) market cap?

Today JNJ has the market capitalization of 487.83B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free